197
Participants
Start Date
October 31, 2013
Primary Completion Date
February 29, 2016
Study Completion Date
January 31, 2023
besifovir 150mg
Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
tenofovir 300mg
Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
Soonchunhyang University Hospital, Cheonan
Hallym University Medical Center, Chuncheon
Wonju Sevrerance Christian Hospital, Wŏnju
Hanyang University Guri Hospital, Guri-si
Ajou University Medical Center, Suwon
Korea University Medical Center, Ansan
Kyungpook National University Hospital, Daegu
Chungnam National University Hospital, Daejeon
Inha University Hospital, Incheon
Inje University Busan Paik Hospital, Pusan
Asan Medical Center, Seoul
Gangnam Severance Hospital, Seoul
Korea University Medical Center, Seoul
Seoul National University Boramae medical Center, Seoul
Seoul National University Hospital, Seoul
Severance Hospital of Yonsei University, Seoul
Soonchunhyang University Hospital, Seoul
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul
The Catholic University of Korea, Seoul St. Vincent's Hospital, Seoul
Ulsan University Hospital,, Ulsan
Lead Sponsor
IlDong Pharmaceutical Co Ltd
INDUSTRY